To Top
0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.

Clear Cell Sarcoma Foundation

Email Address

[email protected]


The Clear Cell Sarcoma Foundation (formerly Sara’s Cure) is a Charleston, SC based 501(c)(3) with a mission to make Clear Cell Sarcoma survivable through education and scientific research while ensuring all patients and caregivers impacted have a voice and platform to enact change and strive towards the cure. With the help of our medical advisors we fund repurposed drug testing on promising drug candidates that have potential as an effective treatment for CCS. We also fund travel support through NORD’s patient assistance program for the Apollo613 clinical trial (NCT04593758), the first of its kind based on solid CCS preclinical evidence. Clear Cell Sarcoma Foundation is where patients have a voice.

Please Note

The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.

NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.